Epigenetic Regulation of T-cell Exhaustion During Treated Chronic HIV Infection
治疗慢性 HIV 感染期间 T 细胞耗竭的表观遗传调控
基本信息
- 批准号:8998914
- 负责人:
- 金额:$ 42.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-02-01 至 2020-01-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAdoptive TransferAllelesAntigen-Presenting CellsAntigensAntiviral AgentsAntiviral ResponseAutologousBiological AssayBiological PreservationBlocking AntibodiesCD8B1 geneCell Culture TechniquesCellsChronicCoupledCytomegalovirusDNA MethylationDNA Modification MethylasesEpigenetic ProcessFoundationsGene ExpressionGene Expression RegulationGene TargetingGenerationsGoalsHIVHIV AntigensHIV InfectionsHealthHighly Active Antiretroviral TherapyID2 geneImmune System DiseasesImmune responseIndividualInfectionInterleukin-15Interleukin-2Interleukin-7KineticsLigationMaintenanceMeasuresMediatingMemoryMethodsMethylationMolecularMorbidity - disease rateNucleic Acid Regulatory SequencesPeptidesReportingResearchSignal TransductionStagingT cell responseT-LymphocyteTherapeuticTimeTranscriptional RegulationViralViruscell killingdesignepigenetic regulationexhaustexhaustioninsightkillingslongitudinal analysismortalitynovelprogramspromoterresearch studyresponsesample fixationtherapeutic vaccinewhole genome
项目摘要
DESCRIPTION: Control of HIV infection in individuals treated with highly active antiretroviral therapy (HAART) is the most effective means for reducing mortality and morbidity of chronically infected individuals. We are now challenged with the goal of functionally curing individuals that have HAART suppressed HIV. The HIV reservoir in HAART treated individuals' remains elusive to our current therapeutic strategies so new strategies are now focused on exploiting the inherent potential of HIV-specific CD8 T cells to target and kill infected cells in order to fully resolve the infection or at least maintain control without the use of HAART. In order to utilize th host repertoire of HIV-specific CD8 T cells to achieve the goal of curing HIV infected individuals,
we have to develop strategies that can stably rejuvenate nonfunctional HIV-specific CD8 T cells so that they re-acquire and retain antiviral functions after expansion. To achieve this goal, we have developed a research program that focuses on understanding the mechanism for acquisition and maintenance of acquired gene expression programs in exhausted HIV-specific CD8 T cells. The following aims are designed to identify genes that are targeted for stable epigenetic programming, develop methods for modifying these programs to erase the transcriptional memory of the HIV-specific CD8 T cell, and reactivate the cells in way that facilitates an effective antiviral response during encounter with an HIV-antigen presenting cell. The specific aims of this proposal are: Aim 1. To determine if gene expression program preservation in exhausted HIV-specific CD8 T cells is coupled to maintenance of DNA methylation at transcriptional regulatory regions. a) To identify T-cell exhaustion gene expression programs that are epigenetically preserved following HAART mediated viral control. b) To identify epigenetically poised transcriptional programs in HIV-specific CD8 T cells from HAART treated donors. Aim 2. To identify DNA methylation programs acquired during differentiation of functional HIV-specific CD8 T cells. a) To identify DNA methylation programs specific to functional HIV-specific CD8 T cells in elite controllers. b) To determine if the functional DNA methylation program in EC HIV-specific CD8 T cells is preserved in virus-specific CD8 T cells from other chronic infections. c) To identify the stage of differentiation whe the functional methylation program is lost during progressive exhaustion of HIV-specific CD8 T cells. Aim 3. To determine if modulation of DNA methylation reprogramming of HIV-specific CD8 T cells by - chain signaling and PD-1 signal blockade rescues HIV specific CD8 function and killing. a) To determine if IL-15 mediated differentiation of exhausted CD8 T cells results in short and long term heritable changes in gene regulations. b) To determine if inhibition of PD-1 engagement enhances DNA methylation re- programming of HIV-specific CD8 T cells.
描述:在接受高效抗逆转录病毒疗法(HAART)治疗的个人中控制艾滋病毒感染是降低慢性感染者死亡率和发病率的最有效手段。我们现在面临的挑战是从功能上治愈那些HAART抑制了艾滋病毒的人。对于我们目前的治疗策略,HAART治疗的个体中的HIV储存库仍然难以捉摸,因此新的策略现在专注于开发HIV特异性CD8 T细胞的内在潜力来靶向并杀死感染细胞,以便完全解决感染问题,或者至少在不使用HAART的情况下保持控制。为了利用HIV特异性CD8 T细胞的宿主库来达到治愈HIV感染者的目标,
我们必须开发一种策略,能够稳定地恢复不起作用的HIV特异性CD8 T细胞的活力,以便它们在扩增后重新获得并保留抗病毒功能。为了实现这一目标,我们开发了一项研究计划,重点是了解在耗尽的HIV特异性CD8T细胞中获得和维持获得性基因表达程序的机制。以下目标旨在识别稳定的表观遗传编程的目标基因,开发修改这些程序的方法以擦除HIV特异性CD8 T细胞的转录记忆,并以便于在与HIV抗原呈递细胞相遇期间有效的抗病毒反应的方式重新激活细胞。这项建议的具体目的是:目的1.确定在疲惫的HIV特异性CD8T细胞中基因表达程序的保存是否与转录调节区DNA甲基化的维持有关。A)确定在HAART介导的病毒控制后表观遗传保存的T细胞耗竭基因表达程序。B)从HAART治疗的捐献者中确定HIV特异性CD8 T细胞中表观遗传平衡的转录程序。目的2.鉴定在功能性HIV特异性CD8T细胞分化过程中获得的DNA甲基化程序。A)在精英控制员中确定针对功能性HIV特异性CD8 T细胞的DNA甲基化程序。B)确定EC HIV特异性CD8T细胞中的功能性DNA甲基化程序是否保存在其他慢性感染的病毒特异性CD8T细胞中。C)确定在HIV特异性CD8 T细胞进行性耗竭过程中功能甲基化程序丢失的分化阶段。目的3.确定链信号和PD-1信号阻断对HIV特异性CD8T细胞DNA甲基化重编程的调节是否能挽救HIV特异性CD8功能和杀伤。A)确定IL-15介导的耗尽CD8 T细胞的分化是否会导致基因调控的短期和长期可遗传变化。B)确定抑制PD-1参与是否增强了HIV特异性CD8 T细胞的DNA甲基化重编程。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Benjamin Alan Youngblood其他文献
Benjamin Alan Youngblood的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Benjamin Alan Youngblood', 18)}}的其他基金
Epigenetic Reprogramming of T cell Exhaustion To Enhance Tumor Immunotherapy
T 细胞耗竭的表观遗传重编程增强肿瘤免疫治疗
- 批准号:
10337284 - 财政年份:2020
- 资助金额:
$ 42.4万 - 项目类别:
Epigenetic Reprogramming of T cell Exhaustion To Enhance Tumor Immunotherapy
T 细胞耗竭的表观遗传重编程增强肿瘤免疫治疗
- 批准号:
10558744 - 财政年份:2020
- 资助金额:
$ 42.4万 - 项目类别:
Epigenetic Regulation of T-cell Exhaustion During Treated Chronic HIV Infection
治疗慢性 HIV 感染期间 T 细胞耗竭的表观遗传调控
- 批准号:
9206463 - 财政年份:2015
- 资助金额:
$ 42.4万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 42.4万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 42.4万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 42.4万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 42.4万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 42.4万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 42.4万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 42.4万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 42.4万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 42.4万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 42.4万 - 项目类别: